India Emerges as Global Pharma’s Capability Cntre Hub: A Look at the Driving Forces and Challenges
India is witnessing a surge in global pharmaceutical companies establishing and expanding their presence, with Hyderabad emerging as a key…
Related Articles
Vibostolimab/Favezelimab Clinical Programs in NSCLC/Lymphoma Discontinued
The phase 3 KeyVibe-003, KeyVibe-007, and KEYFORM-008 trials investigating vibostolimab and favezelimab have been discontinued.
Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML
Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.
Welcome! You are invited to join a webinar: [Live Webinar] – Optimising the management of HR+ HER2- metastatic breast cancer. After registering, you will receive a confirmation email about joining the webinar.
Join this webinar on Wednesday 22 January 2025, 19:00-20:00 CET, where Etienne Brain, Evandro de Azambuja, Valentina Guarneri, Cristina Saura and Hans Wildiers will discuss…
Insights From the CAPTIVATE Trial on Frontline CLL Treatment Strategies
Paolo Ghia, MD, PhD, provides an overview of the CAPTIVATE trial, uncovering what investigators sought to evaluate.
Consolidation Regimen and Cerebral Atrophy in Patients with Primary Central Nervous System Lymphoma
These findings demonstrate accelerated cerebral atrophy in PCNSL after consolidation compared to healthy adults. However, atrophy did not differ by consolidation strategy. These long-term results…
Subgroup analysis from NeoMono: PD-L1 status and pCR in high-risk eTNBC
Hans-Christian Kolberg, MD, Marienhospital Bottrop, Bottrop, Germany, comments on the results of the NeoMono trial, a Phase II neoadjuvant randomized clinical trial in triple-negative breast…
ASH 2024: Changing the Treatment Landscape in Lymphoma
Research presented at ASH 2024 has shed new light on treatment strategies for mantle cell lymphoma and follicular lymphoma.
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic treatment concept that is changing the treatment approach to hematologic malignancies. The development of CAR…
High5 Oncology TV: SABCS 2024
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend. Jetzt gleich den Fragebogen ausfüllen! Durch…
ASH 2024: Advances in CLL/SLL
Trial results presented at the ASH Annual Meeting 2024 could prompt changes in the treatment of CLL and SLL, experts say.